Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
In recent years, GLP1-based treatments for obesity have evolved from being primarily a diabetes-focused strategy to becoming a powerful tool for managing weight and reducing cardiometabolic riskespecially in individuals without type 2 diabetes
The FDA approved Lillys Mounjaro for Type 2 diabetes in 2022 and Zepbound for obesity in 2023
Location: Indianapolis, IndianaWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Zepbound (tirzepatide) and Mounjaro (tirzepatide)FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Eli Lilly promoted Mounjaro and Zepbound in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner, despite FDAs prior correspondence (advisory comments dated June 13, 2022 and June 21, 2022)
The stellate ganglion is a real anatomical target, not a vague idea
This prevents any single area from receiving repeated injections, which can cause tissue changes over time
